Ping Wang1,2, Gang Tan3, Mingxin Zhu3, Weidong Li1,3, Bo Zhai3, Xueying Sun1. 1. a The Hepatosplenic Surgery Center, Department of General Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China. 2. b Department of Interventional Radiology , The Third Affiliated Hospital of Harbin Medical University , Harbin , China. 3. c Department of General Surgery , The Fourth Affiliated Hospital of Harbin Medical University , Harbin , China.
Abstract
BACKGROUND: Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC). Hand-foot skin reaction (HFSR) is a very common side-effect in patients treated with sorafenib, and also affects the treatment schedule and quality of life. However, the association of HFSR and response of HCC to sorafenib remain unclear. METHODS: Databases including PubMed, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials were searched up to May 7th, 2017. Review Manager 5.3 software was adopted for performing meta-analyses, Newcastle-Ottawa Scale for assessing the bias of cohort studies, and GRADEprofler software for further assessing outcomes obtained from meta-analyses. RESULTS: 1478 articles were reviewed, and 12 cohort studies with 1017 participants were included in the analyses. The pooled hazard ratio (HR) of overall survival is 0.45 (95% confidence interval (CI) 0.36, 0.55; P < 0.00001; I2 = 35%). The pooled HR of time to progression is 0.41 (95% CI 0.28, 0.60; P < 0.00001; I2 = 0%). Patients suffering HFSR had significantly better outcomes from sorafenib therapy than those without HFSR. CONCLUSIONS: The results indicate that HFSR is a beneficial indicator for HCC patients receiving sorafenib therapy. However, molecular mechanisms accounting for sorafenib-induced HFSR in HCC patients remain.
BACKGROUND:Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC). Hand-foot skin reaction (HFSR) is a very common side-effect in patients treated with sorafenib, and also affects the treatment schedule and quality of life. However, the association of HFSR and response of HCC to sorafenib remain unclear. METHODS: Databases including PubMed, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials were searched up to May 7th, 2017. Review Manager 5.3 software was adopted for performing meta-analyses, Newcastle-Ottawa Scale for assessing the bias of cohort studies, and GRADEprofler software for further assessing outcomes obtained from meta-analyses. RESULTS: 1478 articles were reviewed, and 12 cohort studies with 1017 participants were included in the analyses. The pooled hazard ratio (HR) of overall survival is 0.45 (95% confidence interval (CI) 0.36, 0.55; P < 0.00001; I2 = 35%). The pooled HR of time to progression is 0.41 (95% CI 0.28, 0.60; P < 0.00001; I2 = 0%). Patients suffering HFSR had significantly better outcomes from sorafenib therapy than those without HFSR. CONCLUSIONS: The results indicate that HFSR is a beneficial indicator for HCCpatients receiving sorafenib therapy. However, molecular mechanisms accounting for sorafenib-induced HFSR in HCCpatients remain.
Authors: E Gabriela Chiorean; Susan M Perkins; R Matthew Strother; Anne Younger; Jennifer M Funke; Safi G Shahda; Noah M Hahn; Kumar Sandrasegaran; David R Jones; Todd C Skaar; Bryan P Schneider; Christopher J Sweeney; Daniela E Matei Journal: Mol Cancer Ther Date: 2020-08-26 Impact factor: 6.261
Authors: Young Youn Cho; Su Jong Yu; Hye Won Lee; Do Young Kim; Wonseok Kang; Yong-Han Paik; Pil Soo Sung; Si Hyun Bae; Su Cheol Park; Young Seok Doh; Kang Mo Kim; Eun Sun Jang; In Hee Kim; Won Kim; Yoon Jun Kim Journal: J Hepatocell Carcinoma Date: 2021-06-18